DHRS9 and neoplasm: The results of univariate analysis revealed that the advanced post-CCRT tumor status, low grade of tumor regression, and high DHRS9 immunoexpression (Figure 3) were considerably unfavorably prognostic of all three endpoints (all p ≤ 0.009): metastasis-free survival (MeFS), local recurrence-free survival (LRFS), and disease-specific survival (DSS) (Table 3).